Examining the neural targets of the AMPA receptor potentiator LY404187 in the rat brain using pharmacological magnetic resonance imaging

Psychopharmacology

Volumn 180, Issue 4, 2005, Pages 743-751

  Jones, Nicholas ^a   O'Neill, Michael J ^b   Tricklebank, Mark ^b   Libri, Vincenzo ^c   Williams, Steve C R ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

AMPA; Cognition; Glutamate; LY293558; LY404187; Memory; MRI; Rat

Indexed keywords

AMPA RECEPTOR AGONIST; AMPA RECEPTOR ANTAGONIST; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; LY 404187; UNCLASSIFIED DRUG;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD VOLUME; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG TARGETING; ELECTROENCEPHALOGRAM; IN VIVO STUDY; MALE; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN BLOOD LEVEL; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN; BRAIN MAPPING; DRUG INTERACTIONS; IMAGE PROCESSING, COMPUTER-ASSISTED; ISOQUINOLINES; MAGNETIC RESONANCE IMAGING; MALE; OXYGEN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; SULFONAMIDES; TETRAZOLES; TIME FACTORS;

EID: 24944576653     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-2254-y     Document Type: Article

References (57)

1. Aguirre GK, Zarahn E, D'Esposito M (1998) The inferential impact of global signal covariates in functional neuroimaging analyses. NeuroImage 8:302-306
2. Alt A, Weiss B, Ogden AM, Knauss JL, Oler J, Ho K, Large TH, Bleakman D (2004) Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro. Neuropharmacology 46:793-806
3. Bandettini PA, Wong EC, Hinks RS, Tikofsky RS, Hyde JS (1992) Time course EPI of human brain function during task activation. Magn Reson Med 25:390-397
4. Baumbarger P, Muhlhauser M, Yang CR, Nisenbaum ES (2001a) LY392098, a novel AMPA receptor potentiator: electrophysiological studies in prefrontal cortical neurons. Neuropharmacology 40:992-1002
5. Baumbarger PJ, Muhlhauser M, Zhai J, Yang CR, Nisenbaum ES (2001b) Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator. J Pharmacol Exp Ther 298:86-102
6. Berg-Johnsen J, Langmoen IA (1992) The effect of isoflurane on excitatory synaptic transmission in the rat hippocampus. Acta Anaesthesiol Scand 36:350-355
7. Bleakman D, Schoepp DD, Ballyk B, Bufton H, Sharpe EF, Thomas K, Ornstein PL, Kamboj RK (1996) Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4AR,6R,8AR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl] decahydroisoquinoline-3 carboxylic acid. Mol Pharmacol 49:581-585
8. Bleakman D, Ogden AM, Ornstein PL, Hoo K (1999) Pharmacological characterization of a GluR6 kainate receptor in cultured hippocampal neurons. Eur J Pharmacol 378:331-337
9. Brett M, Anton J-L, Valabreque R, Poline J-P (2002) Region of interest analysis using an SPM toolbox. Abstract presented at the 8th International Conference on Functional Mapping of the Human Brain, 2-6 June 2002, Sendai, Japan. Available on CD-ROM in NeuroImage, vol 16, no 2
10. Browne SE, McCulloch J (1994) AMPA receptor antagonists and local cerebral glucose utilization in the rat. Brain Res 641:10-20
11. Burdett NG, Menon DK, Carpenter TA, Jones JG, Hall LD (1995) Visualisation of changes in regional cerebral blood flow (rCBF) produced by ketamine using long TE gradient-echo sequences: preliminary results. Magn Reson Imaging 13:549-553
12. Cash D, Read SJ, Lythgoe D, Williams SCR, Roberts TJ, Ireland MD, Smart SC, Hunter AJ (2003) Autoradiographic and functional MRI assessment of rat brain response to amphetamine under halothane and a-chloralose anaesthesia. J Cereb Blood Flow Metab 23:S10
13. Chen YC, Galpern WR, Brownell AL, Matthews RT, Bogdanov M, Isacson O, Keltner JR, Beal MF, Rosen BR, Jenkins BG (1997) Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn Reson Med 38:389-398
14. Czisch M, Wehrle R, Kaufmann C, Wetter TC, Holsboer F, Pollmächer T, Auer DP (2004) Functional MRI during sleep: BOLD signal decreases and their electrophysiological correlates. Eur J Neurosci 20:566-574
15. 14C-2- deoxyglucose autoradiography and c-fos immunocytochemistry. J Cereb Blood Flow Metab 23:S10
16. Fowler JH, Whalley K, Murray T, O'Neill MJ, McCulloch J (2004) The AMPA receptor potentiator LY404187 increases cerebral glucose utilization and c-fos expression in the rat. J Cereb Blood Flow Metab 24:1098-1109
17. Friston KJ, Frith CD, Liddle PF, Dolan RJ, Lammertsma AA, Frackowick AA (1990) The relationship between global and local changes in PET scans. J Cereb Blood Flow Metab 13:1038-1040
18. Friston K, Holmes A, Worsley K, Poline J-B, Frith J, Frackowiak R (1995) Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 2:189-210
19. Gates M, Ogden A, Bleakman D (2001) Pharmacological effects of AMPA receptor potentiators LY392098 and LY404187 on rat neuronal AMPA receptors in vitro. Neuropharmacology 40:984-991
20. Gaza WC, Ribak CE (1997) Immunocytochemical localization of AMPA receptors in the rat inferior colliculus. Brain Res 774:175-183
21. Harel N, Lee S-P, Nagaoka T, Kim D-S, Kim S-G (2002) Origin of negative blood oxygenation level-dependent fMRI signals. J Cereb Blood Flow Metab 22:908-917
22. Hlustik P, Noll DC, Small SL (1998) Suppression of vascular artefacts in functional magnetic resonance images using MR angiograms. Neuroimage 7:224-231
23. Houston GC, Papadakis NG, Carpenter TA, Hall LD, Mukherjee B, James MF, Huang CL (2001) Mapping of brain activation in response to pharmacological agents using fMRI in the rat. Magn Reson Imaging 19:905-919
24. Kalisch R, Elbel G-K, Gössl C, Czisch M, Auer D (2001) Blood pressure changes induced by arterial blood withdrawal influence BOLD signal in anaesthetised rats at 7 Tesla: implications for pharmacologic MRI. Neuroimage 14:891-898
25. Leslie RA, James MF (2000) Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol Sci 21:314-318
26. Logothetis NK, Pauls J, Augath M, Trinath T, Oeltermann A (2001) Neurophysiological investigation of the basis of the fMRI signal. Nature 412:150-157
27. Lowe AS, Barker GJ, Ireland MD, Beech JS, Williams SCR (2005) Estimating global effects from extra-cerebral tissue: inferential utility for pharmacological fMRI. Magn Reson Med, (in press)
28. MacIver MB, Mikulee AA, Amagasu SM, Monroe FA (1996) Volatile anaesthetics depress glutamate transmission via presynaptic actions. Anesthesiology 85:823-824
29. Marota JJ, Mandeville JB, Weisskoff RM, Moskowitz MA, Rosen BR, Kosofsky BE (2000) Cocaine activation discriminates dopaminergic projections by temporal response: an fMRI study in rat. Neuroimage 11:13-23
30. Miu P, Jarvie KR, Radhakrishnan V, Gates MR, Ogden A, Ornstein PL, Zarrinmayeh H, Ho K, Peters D, Grabell J, Gupta A, Zimmerman DM, Bleakman D (2001) Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro. Neuropharmacology 40:976-983
31. Ogawa S, Tank DW, Menon R, Ellermann JM, Kim SG, Merkle H, Ugurbil K (1992) Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci U S A 89:5951-5955
32. Ogawa S, Lee TM, Stepnoski R, Chen W, Zhu XH, Ugurbil K (2000) An approach to probe some neural systems interaction by functional MRI at neural time scale down to milliseconds. Proc Natl Acad Sci U S A 97:11026-11031
33. O'Neill MJ, Lees KR (2002) Chapter 13, stroke. In: Danysz W, Lodge D, Parsons CG (eds) Ionotropic glutamate receptors as therapeutic targets. FP Graham, Johnson City, pp 403-447
34. O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES (2004) AMPA receptor potentiators for the treatment of CND disorders. Curr Drug Targets CNS Neurol Disord 3:181-194
35. Paxinos G, Watson C (1982) The rat brain in stereotaxic coordinates. Academic, New York
36. Pearce RA, Stringer JL, Lothman EW (1989) Effect of volatile anesthetics on synaptic transmission in the rat hippocampus. Anesthesiology 71:591-598
37. Petersson KM, Nichols TE, Poline JB, Holmes AP (1999) Statistical limitations in functional neuroimaging. I. Non-inferential methods and statistical models. Philos Trans R Soc Lond B Biol Sci 354:1239-1260
38. Petralia RS, Wenthold RJ (1992) Light and electron immunocyctochemical localization of AMPA-selective glutamate receptors in the rat brain. J Comp Neurol 318:329-354
39. Plested AJ, Wildman SS, Lieb WR, Franks NP (2004) Determinants of the sensitivity of AMPA receptors to xenon. Anesthesiology 100:347-358
40. Preece M, Mukherjee B, Huang CL, Hall LD, Leslie RA, James MF (2001) Detection of pharmacologically mediated changes in cerebral activity by functional magnetic resonance imaging: the effects of sulpiride in the brain of the anaesthetised rat. Brain Res 916:107-114
41. Quirk JC, Nisenbaum ES (2002) LY404187: a novel positive allosteric modulator of AMPA receptors. CNS Drug Rev 8:255-282
42. Ragowski MA, Gryder D, Castaneda D, Yonekawa W, Banks MK, Li H (2003) GluR5 kainate receptors, seizures and the amygdala. Ann N Y Acad Sci 985:150-162
43. Rasmussen K, Kendrik WT, Kogan JH, Aghajanian GK (1996) A selective AMPA antagonist, LY293558, suppresses morphine withdrawal-induced activation of locus coeruleus neurons and behavioural signs of morphine withdrawal. Neuropsychopharmacology 15:497-505
44. Roberts TJ (2004) Structural and functional imaging in an experimental model of Huntington's disease - mapping pathogenesis and potential therapy. Ph.D. thesis, University of London
45. Salmeron BJ, Stein EA (2002) Pharmacological applications of magnetic resonance imaging. Psychopharmacol Bull 36:102-129
46. Schmid S, Guthmann A, Ruppersberg JP, Herbert H (2001) Expression of AMPA receptor subunit flip/flop splice variants in the rat auditory brainstem and inferior colliculus. J Comp Neurol 430:160-171
47. Schoepp DD, Lodge D, Bleakman D, Leander JD, Tizzano JP, Wright RA, Palmer AJ, Salhoff CR, Ornstein PL (1995) In vitro and in vivo antagonism of AMPA receptor activation by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5yl)ethyl] decahydroisoquinoline-3-carboxylic acid. Neuropharmacology 34:1159-1168
48. Shmuel A, Yacoub E, Pfeufer J, Van der Moortele P-F, Adriany G, Hu X, Ugurbil K (2002) Sustained negative BOLD, blood flow and oxygen consumption response and its coupling to the positive response in the human brain. Neuron 36:1195-1210
49. Simmons RMA, Li DL, Hoo KH, Deverill M, Ornstein PL, Iyengar S (1998) Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat. Neuropharmacology 37:25-36
50. Smith S (2002) Fast robust automated brain extraction. Hum Brain Mapp 17:143-155
51. Smith AT, Williams AL, Singh KD (2004) Negative BOLD in the visual cortex: evidence against blood stealing. Hum Brain Mapp 21:213-220
52. Smolders I, Bortolotto ZA, Clarke VRJ, Warre R, Khan GM, O'Neill MJ, Ornstein PL, Bleakman D, Ogden A, Weiss B, Stables JP, Ho KH, Ebinger G, Collingridge GL, Lodge D, Michotte Y (2002) Antagonists of GLU(K5)-containing kainate receptors prevent pilocarpine-induced limbic seizures. Nat Neurosci 5:796-804
53. Vandergriff J, Huff K, Bond A, Lodge D (2001) Potentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo. Neuropharmacology 40:1003-1009
54. Wenthold RJ, Petralia RS, Blahos J II, Niedzielski AS (1996) Evidence for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons. J Neurosci 16:1982-1989
55. Worsley KJ, Friston KJ (1995) Analysis of fMRI time-series revisited - again. Neuroimage 2:173-181
56. Xu H, Li SJ, Bodurka J, Zhao X, Xi ZX, Stein EA (2000) Heroin-induced neuronal activation in rat brain assessed by functional MRI. Neuroreport 11:1085-1092
57. Yamada KA (2000) Therapeutic potential of positive AMPA receptor modulators in the treatment of neurological disease. Expert Opin Investig Drugs 9:765-768